Adaptimmune Therapeutics Plc, A Leader In T-Cell Therapy To Treat Cancer, Today Announced That The United States Food And Drug Administration (Fda) Has Granted Orphan Drug Designation (Odd) To Spear T-Cells Targeting Mage-A4 (Adaptimmune’S Adp-A2M4 Program) For The Treatment Of Soft Tissue Sarcomas. Orphan Designation By Fda Was Created To Encourage The Development Of Drugs For Rare Diseases, Such As Sarcomas.
